Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
NBRV was delisted on the 31st of July, 2023.
45 hedge funds and large institutions have $85.9M invested in Nabriva Therapeutics plc Ordinary Shares Ireland in 2018 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 17 increasing their positions, 9 reducing their positions, and 10 closing their positions.
89% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 9
30% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 10
17% more capital invested
Capital invested by funds: $73.3M → $85.9M (+$12.6M)
7% more funds holding
Funds holding: 42 → 45 (+3)
71% less call options, than puts
Call options by funds: $32K | Put options by funds: $109K
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FM
Frazier Management
Seattle,
Washington
|
+$12.1M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
+$7.22M |
| 3 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$5.15M |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$3.29M |
| 5 |
O
OrbiMed
New York
|
+$2.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$3.27M |
| 2 |
HIM
Hillhouse Investment Management
Grand Cayman,
Cayman Islands
|
-$2.49M |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
-$1.47M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$765K |
| 5 |
VP
venBio Partners
San Francisco,
California
|
-$619K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Franklin Resources
San Mateo,
California
| – | -$116K | -134 | Closed |
|
|
DS
52
DRW Securities
Chicago,
Illinois
| – | -$87K | -100 | Closed |
|
53
Squarepoint
New York
| – | -$53K | -61 | Closed |
|
|
CSS
54
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$38K | -44 | Closed |
|
|
TRCT
55
Tower Research Capital (TRC)
New York
| – | -$17K | -20 | Closed |
|
NBRV Hedge Fund Activity: Q3 2018 in Review
45 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) for Q3 2018, worth a combined $85.9M — up 17% from $73.3M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new NBRV positions and 10 closed out — a net gain of 3 holders — while 17 added to existing stakes and 9 trimmed.
The largest buyer was Frazier Management, opening a new position worth an estimated $12.1M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $3.27M sold.
- 45 institutional investors held Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) as of Q3 2018, up from 42 in Q2 2018.
- Funds reported $85.9M of Nabriva Therapeutics plc Ordinary Shares Ireland stock for Q3 2018, up 17% quarter-over-quarter.
- 13 funds opened new Nabriva Therapeutics plc Ordinary Shares Ireland positions in Q3 2018 and 10 closed out, a net change of +3 holders.
- The largest Nabriva Therapeutics plc Ordinary Shares Ireland buyer in Q3 2018 was Frazier Management, an estimated $12.1M added.
- The largest Nabriva Therapeutics plc Ordinary Shares Ireland seller in Q3 2018 was Baker Bros. Advisors, an estimated $3.27M sold.
Based on aggregated 13F filings for Q3 2018.